VICTOZA
As listed in the register: VICTOZA 6 mg/ml, solution injectable en stylo prérempli
6 mg · solution injectable
- Prescription only
- Active substance
- Liraglutide
- Made by
- NOVO NORDISK (DANEMARK)
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Liraglutide). It describes the substance, not this exact product.
Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37).
GLP-1(7-37) represents <20% of total circulating endogenous GLP-1.
Liraglutide is endogenously metabolized in a similar manner to large proteins without a specific organ as a major route of elimination.
Only a minor part of the administered radioactivity was excreted as liraglutide-related metabolites in urine or feces (6% and 5%, respectively).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-27
Safety of the active substance
From the US prescribing label for the same active substance (Liraglutide). It describes the substance, not this exact product.
WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.
- Liraglutide is contraindicated in patients with a: personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )]. serious hypersensitivity reaction to liraglutide or to any of the excipients in liraglutide injection.
- Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with liraglutide injection [see Warnings and Precautions ( 5.7 )].
- Patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.
- (4) Patients with a serious hypersensitivity reaction to liraglutide or any of the excipients in liraglutide injection.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States15 matching products
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands14 matching products
- Ablymico 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Byesilor 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Diavic 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Diavorin 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Ejulir 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Liraglutide STADA 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
- Liraglutide Teva 6 mg/ml 6 mg/ml · oplossing voor injectie
- Liraglutide Xiromed 6 mg/ml oplossing voor injectie in een voorgevulde pen 6 mg/ml · oplossing voor injectie
Details
| Made by | NOVO NORDISK (DANEMARK) |
|---|---|
| Active substance | Liraglutide |
| Strength | 6 mg |
| Form | solution injectable |
| Route | sous-cutanée |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/09/529 |
| Name in the register | VICTOZA 6 mg/ml, solution injectable en stylo prérempli |
| Packs | 2 cartouche(s) en verre dans stylo pré-rempli de 3 ml |
| CIS | 62645506 |
| CIP13 | 3400939632360 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.